Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
The approval of CASGEVY, the first CRISPR-based medicine, for transfusion-dependent ß-thalassemia and sickle cell disease, signifies a significant milestone for the company. The company has upcoming catalysts, including updates on CASGEVY, the CTX112 program, CTX131, CTX211, CTX310, CTX320, and undisclosed targets, which could validate its technology and drive value creation. Looking for a helping hand in the market? Members of Compounding Healthcare get exclusive ideas and guidance to navigate any climate. Learn More » It has been over 4 years since my last CRISPR Therapeutics ( NASDAQ: CRSP article when I was hesitant about gathering a heavy CRSP position due to the ticker's premium valuation, volatility, and the company's young pipeline. Yet, I was optimistic about the company's prospects of their expansive pipeline, and partnerships. Despite my concerns, I decided to initiate a long-term investment to gain exposure to the gene editing industry and benefit from an early entr
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Vertex (VRTX) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note [Yahoo! Finance]Yahoo! Finance
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Reuters]Reuters
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Now Is The Time To Buy [Seeking Alpha]Seeking Alpha
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website